Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12601439 | 0.83 | — | — | |
| SCHEMBL5024582 | 0.81 | CA1 (0.39) | KDM4EALOX15USP2ALDH1A1LMNA | |
| SCHEMBL3655503 | 0.77 | CA1 (0.46) | KDM4EALOX15USP2ALDH1A1LMNA | |
| SCHEMBL17183005 | 0.77 | CA1 (0.46) | KDM4EALOX15USP2ALDH1A1LMNA | |
| SCHEMBL17183011 | 0.77 | CA1 (0.46) | KDM4EALOX15USP2ALDH1A1LMNA | |
| SCHEMBL4615228 | 0.75 | — | — | |
| SCHEMBL153103 | 0.75 | — | — | |
| SCHEMBL28046726 | 0.73 | — | — | |
| SCHEMBL11056239 | 0.73 | — | — | |
| SCHEMBL27845994 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2762485-B1 | METHOD FOR PRODUCING POLYPEPTIDE FRAGMENT WITH HIGH EFFICIENCY, WHICH IS SUITABLE FOR NCL METHOD | GLYTECH INC (JP) | 2018-08-01 | — | — | EP | disclosed |
| EP-1379232-B1 | N-ACETYLCYSTEINE COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF DRUG TOXICITY | UNIV LELAND STANFORD JUNIOR (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20140377807-A1 | METHOD FOR PRODUCING POLYPEPTIDE FRAGMENT WITH HIGH EFFICIENCY, WHICH IS SUITABLE FOR NCL METHOD | GLYTECH, INC. (JP) | 2014-12-25 | — | — | US | disclosed |
| CN-104080796-A | Method for producing polypeptide fragment with high efficiency, which is suitable for NCL method | GLYTECH INC | 2014-10-01 | — | — | CN | disclosed |
| EP-2762485-A1 | METHOD FOR PRODUCING POLYPEPTIDE FRAGMENT WITH HIGH EFFICIENCY, WHICH IS SUITABLE FOR NCL METHOD | Glytech, Inc. (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-7442459-B2 | Solid electrolyte, membrane and electrode assembly, and fuel cell | FUJIFILM CORPORATION (JP) | 2008-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140377807-A1 | METHOD FOR PRODUCING POLYPEPTIDE FRAGMENT WITH HIGH EFFICIENCY, WHICH IS SUITABLE FOR NCL METHOD | MET, NCLN, LNPEP | PTGS1 4808/4885PDE4A 4847/4885KDM4E 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.